Table 4.
Multivariable estimates of survival for women with intermediate risk tumors stratified by performance of lymphadenectomy.
| Covariate | Lymph Node Dissection Performed | Lymph Node Dissection Not Performed |
|---|---|---|
| Follow-up months | ||
| Median (range) | 66.40 (0.03–187.33) | 65.88 (0.03–186.41) |
| Chemotherapy | ||
| No | Referent | Referent |
| Yes | 0.77 (0.62–0.97)* | 0.73 (0.52–1.03) |
| Age | ||
| <40 | Referent | Referent |
| 40–49 | 0.94 (0.61–1.45) | 3.84 (1.06–13.88)* |
| 50–59 | 1.25 (0.80–1.95) | 3.75 (1.06–13.29)* |
| 60–69 | 1.67 (1.07–2.60)* | 6.42 (1.86–22.22)* |
| ≥70 | 3.22 (1.98–5.22)* | 9.44 (2.69–33.14)* |
| Race | ||
| White | Referent | Referent |
| Black | 1.14 (0.69–1.88) | 1.71 (0.97–3.04) |
| Hispanic | 0.62 (0.34–1.15) | 0.41 (0.09–1.92) |
| Other/unknown | 1.07 (0.70–1.65) | 1.29 (0.63–2.63) |
| Insurance | ||
| Private | Referent | Referent |
| Medicaid | 2.12 (1.25–3.61)* | 1.99 (0.91–4.36) |
| Medicare | 1.36 (0.98–1.89) | 1.77 (1.15–2.72)* |
| Uninsured | 1.42 (0.85–2.37) | 1.66 (0.69–4.00) |
| Other government/unknown | 1.31 (0.82–2.10) | 2.03 (1.00–4.12) |
| Facility Location | ||
| Eastern | Referent | Referent |
| Midwest | 1.52 (1.12–2.07)* | 1.13 (0.71–1.79) |
| South | 1.41 (1.04–1.93)* | 1.14 (0.73–1.77) |
| West | 1.03 (0.70–1.51) | 0.67 (0.37–1.21) |
| Facility Type | ||
| Community cancer | Referent | Referent |
| Academic/research | 0.97 (0.62–1.51) | 0.96 (0.56–1.64) |
| Comprehensive community cancer | 0.84 (0.54–1.31) | 1.16 (0.70–1.93) |
| Other | 2.60 (1.54–4.39)* | - ╪ |
| Urban/Rural | ||
| Metropolitan | Referent | Referent |
| Urban | 0.90 (0.67–1.21) | 1.30 (0.85–1.97) |
| Rural | 0.52 (0.20–1.32) | 0.36 (0.04–3.02) |
| Unknown | 2.05 (1.39–3.02)* | 1.60 (0.86–2.96) |
| Histology | ||
| Serous | Referent | Referent |
| Mucinous | 1.24 (0.91–1.68) | 0.99 (0.66–1.49) |
| Endometrioid | 0.85 (0.64–1.13) | 0.76 (0.51–1.12) |
| Clear cell | - | - |
| Transitional cell | -╪ | - |
| Epithelial tumor NOS | 0.93 (0.60–1.44) | 0.66 (0.36–1.24) |
| Stage | ||
| 1A | Referent | Referent |
| 1B | 1.64 (1.16–2.31)* | 1.49 (0.93–2.40) |
| 1C | - | - |
| Year of Diagnosis | ||
| 1998 | Referent | Referent |
| 1999 | 1.29 (0.78–2.14) | 1.00 (0.53–1.87) |
| 2000 | 1.64 (1.04–2.58)* | 1.04 (0.56–1.90) |
| 2001 | 1.27 (0.76–2.12) | 0.77 (0.40–1.45) |
| 2002 | 1.30 (0.79–2.13) | 0.86 (0.44–1.67) |
| 2003 | 1.02 (0.58–1.78) | 0.86 (0.43–1.71) |
| 2004 | 1.42 (0.81–2.49) | 1.11 (0.51–2.44) |
| 2005 | 1.84 (1.12–3.01)* | 0.68 (0.34–1.34) |
| 2006 | 1.01 (0.53–1.93) | 0.79 (0.34–1.81) |
| 2007 | 1.13 (0.63–2.03) | 1.04 (0.48–2.28) |
| 2008 | 1.12 (0.56–2.21) | 0.90 (0.38–2.10) |
| 2009 | 0.90 (0.44–1.83) | 1.56 (0.65–3.75) |
| 2010 | 0.84 (0.30–2.34) | 1.61 (0.61–4.20) |
| 2011 | 1.35 (0.58–3.12) | 0.69 (0.15–3.26) |
Adjusted hazard ratio (95% confidence interval).
╪
Non-estimable.
306 patients with missing follow-up time, vital status, or facility identifier were excluded; 2,735 and 736 patients were modeled in lymph nodes dissection performed and node dissection not performed.
Age, race, insurance status, facility region, facility type, facility location, histology, stage, lymph node examination, and year of diagnosis were included in the marginal Cox proportional hazard models accounting for facility-level clustering.